Experience of Comamonas acidovorans keratitis with delayed onset and treatment response in immunocompromised cornea.
OBJECTIVE
To report 2 cases of Comamonas acidovorans keratitis in immunocompromised cornea.


METHODS
A complete review of the medical records of the two cases of Comamonas acidovorans keratitis.


RESULTS
We found some similarities in clinical courses of two cases. Both of them showed development of keratitis during the management with corticosteroids, delayed onset, slow response to antibiotics, and relatively less affected corneal epithelium.


CONCLUSIONS
Comamonas acidovorans is known as a less virulent organism. However it can cause an indolent infection that responds slowly even to adequate antibiotics therapy in immunocompromised corneas.
Lee
Sang Mok
SM
Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea.
Kim
Mee Kum
MK
Lee
Jae Lim
JL
Wee
Won Ryang
WR
Lee
Jin Hak
JH
D000583:Amikacin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002442:Ceftazidime / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D003320:Corneal Ulcer / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D020605:Delftia acidovorans / Q000302:isolation & purification*; D004359:Drug Therapy, Combination; D015818:Eye Infections, Bacterial / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D016905:Gram-Negative Bacterial Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D000583:Amikacin; D002442:Ceftazidime